Chapter 11

Prevention of HPV-Associated Diseases

Azam Bolhassani and Elnaz Agi

Abstract

HPV infection as the etiologic agent of cervical cancer and also other epithelial cancers, has led to the development of three FDA-approved prophylactic HPV vaccines composed of virus-like particles (VLPs). Development of prophylactic HPV vaccines could decrease HPV-associated diseases especially HPV-16 and -18 in the world. Recently, in order to enhance protection against other HPV genotypes, second-generation vaccines are underway. For example, A novel safe HPV L1-based nonavalent vaccine was designed to prevent precancerous lesions related to high-risk HPV types 16/18/31/33/45/52/58, as well as anogenital warts associated with HPV types 6/11. This vaccine is in the advanced stage of phase III clinical trials. Other second-generation vaccines were based on L1-pentameric subunits and also the minor capsid protein L2 that have shown to be effective in preclinical studies. In this chapter, some major methods about the prevention of HPV-associated diseases will be discussed.

Total Pages: 159-163 (5)

Purchase Chapter  Book Details

RELATED BOOKS

.COVID-19: Epidemiology, Biochemistry, and Diagnostics.
.Frontiers in Anti-infective Agents.
.Coronaviruses.
.Influenza: A Century of Research.